Posted on

Silo Wellness Announces the First-of-Its-Kind U.S.-Legal Psychedelic Wellness Nature Retreat in Oregon

SPRINGFIELD, Ore., Nov. 13, 2020 (GLOBE NEWSWIRE) — Oregon’s Silo Wellness (“Silo”), an early mover in the psychedelic mushroom space is pleased to announce that it is organizing a ketamine-assisted wellness retreat in Oregon under the care of Dr. Matthew Hicks, ND, MS. This will add to the existing psilocybin operations in Jamaica, where Silo currently has mushroom and truffle cultivation, as well as multiple psychedelic retreat offerings. In 2019, the company announced its patent-pending psilocybin nasal spray it developed in Jamaica.

Following the landmark passing of Oregon’s Measure 109 authorizing the Oregon Health Authority to permit licensed service providers to administer psilocybin in therapeutic settings (after a two-year rulemaking development period), Silo has positioned itself with a unique alternative to the brick-and-mortar ketamine clinic, similar to the psychedelic retreats it offers in Jamaica.

“We can take our Jamaica psilocybin retreat protocols and use them in Oregon ketamine retreats and then later in Oregon psilocybin retreats once that program is implemented,” explained Silo Director of Science pharmacologist Parag Bhatt, PhD. “This US-based psychedelic retreat model would allow the addition of psilocybin and other natural psychedelics if and when other states come online, similar to the medical marijuana legalization trajectory that began back in 1995 in California.”

The Oregon ketamine-assisted wellness retreat establishes a United States base to meet the needs of those suffering from emotional, spiritual or psychological pain but unable to make a trip to Jamaica to experience legal psilocybin. A short flight from Seattle and San Francisco, and less than a 2.5-hour drive from Portland, Silo’s first Oregon retreat will allow qualifying participants to experience Ketamine-assisted wellness benefits alongside nature. “While ketamine clinics are a convenient and necessary choice for many, psychedelic-enhanced therapy depends a lot on mindset and setting,” said Silo medical advisor and AIMS Clinic of Seattle co-founder Sunil Aggarwal, MD, PhD, FAAPMR. “Traditionally, however, the natural setting has been preferred for those experiencing non-ordinary states of consciousness.”

Silo has engaged experienced ketamine-assisted psychotherapy (KAP) clinic operators Drs. Aggarwal and Leanna Standish, ND, PhD, LAc, FABNO to help develop the screening, retreat agenda, and protocols, as well as research outcomes.

“We welcome the opportunity to activate on this aspect of our business,” stated Douglas Gordon, Silo’s Chief Executive Officer.   “Silo moved early precisely to be in pole position to deliver on these types of experiences and with the passing of the bill last week, we are both excited and motivated by the opportunity to help patients and validate our business model.”

Oregon Attorney Mike Arnold, founder of Silo Wellness, stated, “We are very excited about the opportunity that Oregon, being the first state to legalize psychedelic mushrooms, presents Silo. Given our experience cultivating and harvested psychedelic mushrooms in Jamaica and our unique metered-dosing delivery mechanism via our patent-pending psilocybin nasal spray, we feel Silo is poised to be an industry leader, not only in Oregon and Jamaica, but in other jurisdictions that will inevitably follow our state’s lead.”

The agenda will be centered on integration in nature after the ketamine sessions using the natural surroundings with a series of memorable elements, including dropping participants off at their cabins via raft after their whitewater mindfulness excursion. Additionally, the waterfall meditation hikes and the total immersion into all the Pacific Northwest has to offer, makes this a unique opportunity for anyone looking to balance mind, body, and spirit while communing with nature.

The pharmacology and physician team have begun offering initial intake consultations for a January 2021 retreat. The Silo Wellness team is also offering this unique opportunity to Oregon physicians working in the ketamine space. “We are looking forward to collaborating with local practitioners to help share with the world the KAP clinical and retreat models,” stated Dr. Aggarwal. “It’s important that we get the word out that these unique treatment alternatives are now available and legal in the United States, and there’s no better way to train than alongside others immersed in the process.”

Silo is collaborating with Portland, Oregon, ketamine clinic operator Dr. Matthew Hicks, ND, MS. Dr. Hicks brings experience in both ketamine therapy and integrative approaches to mental health care.

Silo Wellness is also pleased to announce the engagement of Dave Kopilak, attorney at law, of Emerge Law Group in Portland, who was the primary drafter of Oregon’s newly passed psilocybin law. “Being a resident of Oregon and practicing law here beginning in 2001, I knew the importance of partnering with the top legal professionals in the psychedelic arena,” Arnold stated. “I am pleased to have been working directly with Dave Kopilak and his team on our Oregon ketamine retreat project and look forward to working with them in preparation for Oregon psilocybin therapy. It is certainly a wonderous time to be collaborating with other Oregonians to shape an industry.”

Silo Wellness is Poised to Enter the Oregon Psilocybin Market

With the passing of the Oregon Measure 109, the company intends to offer psilocybin retreats in Oregon as well as pursue a clinical psilocybin-assisted counseling element with patients using the psilocybin nasal spray prior to sessions through either licensees or through the company’s own branded psilocybin service centers. “When I entered the psilocybin space in 2018, I intended to build a company with strong assets ready for what I saw back then as Oregon’s inevitable legalization,” stated Silo Wellness founder Mike Arnold. “With our extensive local Oregon connections, our experience successfully cultivating psychedelic mushrooms in Jamaica since January 2020, our IP portfolio, and now our presence in the psychedelic retreat space in Oregon, we are well positioned to apply for Oregon psilocybin licenses as a company with authentic Oregon roots.”

“While we can’t export our psychedelic mushrooms and truffles from Jamaica, we can export the systems, people, policies, and procedures in order to be turnkey ready in Oregon, the state I have called home for 22 years,” Arnold continued. “We are locked and loaded to meet Silo’s mission to put psychedelics in the hands of people in need as inexpensively and expeditiously as possible. We are blessed to be able refine our psychedelic retreat and cultivation systems in a country a few hundred miles off the coast of the United States and are looking forward to bringing that system to Oregon.”

About Silo Wellness

Silo Wellness is an early mover in the psychedelics and functional mushrooms space. With current operations ongoing in Jamaica for psilocybin cultivation and retreats, the company intends to expand operations and sales to the states and provinces when and if they legalize mushrooms. On August 25, 2020, FlyOverture Equity Inc., operating as Silo Wellness executed an amalgamation agreement with Yukoterre Resources, Inc. (CSE:YT), a company listed on the Canadian Stock Exchange for a go-public transaction via a reverse take-over.

About AIMS Institute

The Advanced Integrative Medical Science Institute, PLLC, of Washington (“AIMS”) (www.aimsinstitute.net) is a leader and early mover in the ketamine-assisted psychotherapy clinic space. Co-founder Dr. Leanna Standish, ND, PhD, LAc, FABNO, is a neuroscientist and naturopathic physician who holds faculty appointments at the University of Washington School of Medicine in the Radiology Department as well as at Bastyr University. She specializes in integrative oncology and neurology. She leads cancer research teams and holds an FDA IND for a phase I clinical trial of ayahuasca, a psychoactive Amazonian tea.  Co-founder Dr. Sunil Aggarwal, MD, PhD, FAAPMR is a Clinical Assistant Professor at the University of Washington School of Medicine, an Affiliate Assistant Professor of Geography at UW, and a Faculty Member of the National Family Medicine Residency. Dr. Aggarwal is also an Associate Member of the New York Academy of Medicine and the Humboldt Institute for Interdisciplinary Marijuana Research. He is also currently an Associate Medical Director of MultiCare Hospice. He serves on the Editorial Advisory Board of the National Cancer Institute’s PDQ Cancer CAM information summary on cannabis and cannabinoids. He has published dozens of peer-reviewed articles and chapters and has been qualified as an expert in cannabis and psilocybin medical and religious use in county, state, and federal courts.

About Dr. Matthew Hicks

Matthew Hicks, ND, MS is a naturopathic physician and holds a degree in integrative medical research. He has published papers on empathy and mindfulness and is completing a certificate in psychedelic therapy and research from the California Institute of Integral Studies. He is the host of the Integrative Psychiatry Review Podcast and founder of Synaptic Integrative Care and Training Institute (https://synaptic.care/) of Portland Oregon, which offers integrative mental health services including ketamine-assisted treatments as well as training on psychedelic therapy. Matthew also happens to be a veteran with a passion for helping other veterans resolve their traumas. He is originally from the Kansas City, Missouri area and attended undergrad at UMKC.

Further Information

For further information, please contact:

Silo Wellness
Mike Arnold, Founder/President
5729 Main St., Suite 148
Springfield, OR 97478
Tel: 541-525-9190
Web: www.SiloWellness.com
Email: press [at symbol] silo wellness [dot com]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. SILO assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities from Silo Wellness in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Posted on

Silo Wellness Announces the First-of-Its-Kind U.S.-Legal Psychedelic Wellness Nature Retreat in Oregon

SPRINGFIELD, Ore., Nov. 13, 2020 (GLOBE NEWSWIRE) — Oregon’s Silo Wellness (“Silo”), an early mover in the psychedelic mushroom space is pleased to announce that it is organizing a ketamine-assisted wellness retreat in Oregon under the care of Dr. Matthew Hicks, ND, MS. This will add to the existing psilocybin operations in Jamaica, where Silo currently has mushroom and truffle cultivation, as well as multiple psychedelic retreat offerings. In 2019, the company announced its patent-pending psilocybin nasal spray it developed in Jamaica.

Following the landmark passing of Oregon’s Measure 109 authorizing the Oregon Health Authority to permit licensed service providers to administer psilocybin in therapeutic settings (after a two-year rulemaking development period), Silo has positioned itself with a unique alternative to the brick-and-mortar ketamine clinic, similar to the psychedelic retreats it offers in Jamaica.

“We can take our Jamaica psilocybin retreat protocols and use them in Oregon ketamine retreats and then later in Oregon psilocybin retreats once that program is implemented,” explained Silo Director of Science pharmacologist Parag Bhatt, PhD. “This US-based psychedelic retreat model would allow the addition of psilocybin and other natural psychedelics if and when other states come online, similar to the medical marijuana legalization trajectory that began back in 1995 in California.”

The Oregon ketamine-assisted wellness retreat establishes a United States base to meet the needs of those suffering from emotional, spiritual or psychological pain but unable to make a trip to Jamaica to experience legal psilocybin. A short flight from Seattle and San Francisco, and less than a 2.5-hour drive from Portland, Silo’s first Oregon retreat will allow qualifying participants to experience Ketamine-assisted wellness benefits alongside nature. “While ketamine clinics are a convenient and necessary choice for many, psychedelic-enhanced therapy depends a lot on mindset and setting,” said Silo medical advisor and AIMS Clinic of Seattle co-founder Sunil Aggarwal, MD, PhD, FAAPMR. “Traditionally, however, the natural setting has been preferred for those experiencing non-ordinary states of consciousness.”

Silo has engaged experienced ketamine-assisted psychotherapy (KAP) clinic operators Drs. Aggarwal and Leanna Standish, ND, PhD, LAc, FABNO to help develop the screening, retreat agenda, and protocols, as well as research outcomes.

“We welcome the opportunity to activate on this aspect of our business,” stated Douglas Gordon, Silo’s Chief Executive Officer.   “Silo moved early precisely to be in pole position to deliver on these types of experiences and with the passing of the bill last week, we are both excited and motivated by the opportunity to help patients and validate our business model.”

Oregon Attorney Mike Arnold, founder of Silo Wellness, stated, “We are very excited about the opportunity that Oregon, being the first state to legalize psychedelic mushrooms, presents Silo. Given our experience cultivating and harvested psychedelic mushrooms in Jamaica and our unique metered-dosing delivery mechanism via our patent-pending psilocybin nasal spray, we feel Silo is poised to be an industry leader, not only in Oregon and Jamaica, but in other jurisdictions that will inevitably follow our state’s lead.”

The agenda will be centered on integration in nature after the ketamine sessions using the natural surroundings with a series of memorable elements, including dropping participants off at their cabins via raft after their whitewater mindfulness excursion. Additionally, the waterfall meditation hikes and the total immersion into all the Pacific Northwest has to offer, makes this a unique opportunity for anyone looking to balance mind, body, and spirit while communing with nature.

The pharmacology and physician team have begun offering initial intake consultations for a January 2021 retreat. The Silo Wellness team is also offering this unique opportunity to Oregon physicians working in the ketamine space. “We are looking forward to collaborating with local practitioners to help share with the world the KAP clinical and retreat models,” stated Dr. Aggarwal. “It’s important that we get the word out that these unique treatment alternatives are now available and legal in the United States, and there’s no better way to train than alongside others immersed in the process.”

Silo is collaborating with Portland, Oregon, ketamine clinic operator Dr. Matthew Hicks, ND, MS. Dr. Hicks brings experience in both ketamine therapy and integrative approaches to mental health care.

Silo Wellness is also pleased to announce the engagement of Dave Kopilak, attorney at law, of Emerge Law Group in Portland, who was the primary drafter of Oregon’s newly passed psilocybin law. “Being a resident of Oregon and practicing law here beginning in 2001, I knew the importance of partnering with the top legal professionals in the psychedelic arena,” Arnold stated. “I am pleased to have been working directly with Dave Kopilak and his team on our Oregon ketamine retreat project and look forward to working with them in preparation for Oregon psilocybin therapy. It is certainly a wonderous time to be collaborating with other Oregonians to shape an industry.”

Silo Wellness is Poised to Enter the Oregon Psilocybin Market

With the passing of the Oregon Measure 109, the company intends to offer psilocybin retreats in Oregon as well as pursue a clinical psilocybin-assisted counseling element with patients using the psilocybin nasal spray prior to sessions through either licensees or through the company’s own branded psilocybin service centers. “When I entered the psilocybin space in 2018, I intended to build a company with strong assets ready for what I saw back then as Oregon’s inevitable legalization,” stated Silo Wellness founder Mike Arnold. “With our extensive local Oregon connections, our experience successfully cultivating psychedelic mushrooms in Jamaica since January 2020, our IP portfolio, and now our presence in the psychedelic retreat space in Oregon, we are well positioned to apply for Oregon psilocybin licenses as a company with authentic Oregon roots.”

“While we can’t export our psychedelic mushrooms and truffles from Jamaica, we can export the systems, people, policies, and procedures in order to be turnkey ready in Oregon, the state I have called home for 22 years,” Arnold continued. “We are locked and loaded to meet Silo’s mission to put psychedelics in the hands of people in need as inexpensively and expeditiously as possible. We are blessed to be able refine our psychedelic retreat and cultivation systems in a country a few hundred miles off the coast of the United States and are looking forward to bringing that system to Oregon.”

About Silo Wellness

Silo Wellness is an early mover in the psychedelics and functional mushrooms space. With current operations ongoing in Jamaica for psilocybin cultivation and retreats, the company intends to expand operations and sales to the states and provinces when and if they legalize mushrooms. On August 25, 2020, FlyOverture Equity Inc., operating as Silo Wellness executed an amalgamation agreement with Yukoterre Resources, Inc. (CSE:YT), a company listed on the Canadian Stock Exchange for a go-public transaction via a reverse take-over.

About AIMS Institute

The Advanced Integrative Medical Science Institute, PLLC, of Washington (“AIMS”) (www.aimsinstitute.net) is a leader and early mover in the ketamine-assisted psychotherapy clinic space. Co-founder Dr. Leanna Standish, ND, PhD, LAc, FABNO, is a neuroscientist and naturopathic physician who holds faculty appointments at the University of Washington School of Medicine in the Radiology Department as well as at Bastyr University. She specializes in integrative oncology and neurology. She leads cancer research teams and holds an FDA IND for a phase I clinical trial of ayahuasca, a psychoactive Amazonian tea.  Co-founder Dr. Sunil Aggarwal, MD, PhD, FAAPMR is a Clinical Assistant Professor at the University of Washington School of Medicine, an Affiliate Assistant Professor of Geography at UW, and a Faculty Member of the National Family Medicine Residency. Dr. Aggarwal is also an Associate Member of the New York Academy of Medicine and the Humboldt Institute for Interdisciplinary Marijuana Research. He is also currently an Associate Medical Director of MultiCare Hospice. He serves on the Editorial Advisory Board of the National Cancer Institute’s PDQ Cancer CAM information summary on cannabis and cannabinoids. He has published dozens of peer-reviewed articles and chapters and has been qualified as an expert in cannabis and psilocybin medical and religious use in county, state, and federal courts.

About Dr. Matthew Hicks

Matthew Hicks, ND, MS is a naturopathic physician and holds a degree in integrative medical research. He has published papers on empathy and mindfulness and is completing a certificate in psychedelic therapy and research from the California Institute of Integral Studies. He is the host of the Integrative Psychiatry Review Podcast and founder of Synaptic Integrative Care and Training Institute (https://synaptic.care/) of Portland Oregon, which offers integrative mental health services including ketamine-assisted treatments as well as training on psychedelic therapy. Matthew also happens to be a veteran with a passion for helping other veterans resolve their traumas. He is originally from the Kansas City, Missouri area and attended undergrad at UMKC.

Further Information

For further information, please contact:

Silo Wellness
Mike Arnold, Founder/President
5729 Main St., Suite 148
Springfield, OR 97478
Tel: 541-525-9190
Web: www.SiloWellness.com
Email: press [at symbol] silo wellness [dot com]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. SILO assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities from Silo Wellness in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Posted on

MindMed Announces Q3 2020 Financial Results; Cash Reserves Total $37.8 million USD ($50.1 million CAD) Post October Financing

TORONTO, Nov 13, 2020 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF), a leading psychedelic medicine biotech company, has announced its third quarter financial results for the three and nine months ended September 30, 2020.

 

Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com.

 

Financial Highlights (in USD)

Total assets as of September 30, 2020 were $23.7 million, including $18.2 million in cash.

Net and comprehensive loss of $8.6 million for the three months ended Sep 30,2020, and $21.4 million for the nine months ended September 30, 2020.

Posted on

Microdosing improves mental health, creativity, focus, and sociability

Microdosing Psychedelics Is Trendy, But Does It Work? Here’s What Science Says

In a study published in Psychopharmacology, 44% of survey respondents reported that microdosing psychedelics significantly improved their mental health, with 50% reporting that they were able to stop taking antidepressants completely. In a separate study, microdosers were significantly less likely to report a history of substance use or anxiety disorders, with an average dose of 0.3 grams of psilocybin or 13 micrograms of LSD taken every three days. In the 2019 Global Drug Survey, microdosers often reported “enhanced mood, creativity, focus, and sociability”, with the most common reported challenge of microdosing being “none”.

PDF of article

Posted on

AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds

Lead compounds have anti-coronavirus activity, including against SARS-CoV and SARS-CoV2

Lead compounds have anti-coronavirus activity, including against SARS-CoV and SARS-CoV2

PR Newswire

NEW YORK, Nov. 13, 2020

NEW YORK , Nov. 13, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the publication of positive results from a study of antiviral activity of FDA approved drugs in a peer-reviewed article in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).  The publication reports studies on newly discovered antiviral compounds that were developed using a computer modeling approach.  The lead compounds were found to have broad-spectrum antiviral activity, inhibiting influenza virus, Ebola, Marburg, MERS-CoV, SARS-CoV, and SARS-CoV2, the virus that causes COVID-19.

(PRNewsfoto/AIkido Pharma Incorporated)

Mr. Anthony Hayes , CEO of AIkido stated, “The results of this peer reviewed study provide encouraging data for Company’s newly licensed compounds. I am particularly excited with the data that demonstrates inhibition of SARS-CoV2 by the lead compounds.  This represents yet another solid validation of University of Maryland, Baltimore’s (UMB) antiviral platform, to which we are the exclusive licensee.  In addition, this article provides a significant amount of substantive information about the technology we have licensed from UMB.  I encourage our shareholders who want more information about the technology to review the article.”

The full article is available at https://www.pnas.org/content/early/2020/11/11/2012939117

The Company previously executed a Master License Agreement with UMB for specific antiviral compounds discovered by UMB that seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, SARS-CoV2, MERS-CoV, Ebolavirus and Marburg virus. The technology is covered by two patent applications already on file with the United States Patent and Trademark Office. The Company previously executed a Sponsored Research Agreement with UMB to support the development of the technology.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas , Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

 

CisionView original content to download multimedia: http://www.prnewswire.com/news-releases/aikido-pharma-inc-announces-publication-of-favorable-peer-reviewed-study-of-newly-licensed-antiviral-compounds-301172659.html

SOURCE AIkido Pharma Inc.

News Provided by PR Newswire via QuoteMedia

Posted on

COMPASS Pathways plc announces financial results for third quarter 2020

Highlights include $146.6 million IPO, continued progress with phase IIb psilocybin therapy clinical trial, strengthened board and leadership team, and launch of Drug Discovery Center


Third quarter and post-period highlights:

  • Completed upsized initial public offering (IPO) on Nasdaq, raising $146.6 million
  • Continued to progress phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression
  • Strengthened board and leadership team with appointments of Linda McGoldrick as non-Executive Director; Greg Ryslik as Senior Vice President, Data Science, Machine Learning and Digital Health Research; and Stephen Schultz as Senior Vice President, Investor Relations
  • Established Drug Discovery Center with the University of the Sciences in Philadelphia, PA

Conference call today at 1.00pm GMT (8.00am ET)

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter of 2020 and gave an update on recent progress across its business.

George Goldsmith, Chairman, CEO and Co-founder, COMPASS Pathways, said, “This has been a significant quarter, with an IPO that gives us the funds needed to advance our mission and transform mental health care. Recent hires for the company build further important expertise within our strong leadership team, including in data science and digital health, which will be core to the future of mental health care. We remain fully focused on execution of our phase IIb trial investigating our COMP360 psilocybin therapy for treatment-resistant depression and, with scientific partners in our recently established Drug Discovery Center, are also evaluating the potential of early stage compounds to address mental health challenges.”

Corporate highlights

In September 2020, we completed our IPO of 8,625,000 American Depositary Shares (ADSs) representing 8,625,000 ordinary shares at a price of $17.00 per ADS. This included 1,125,000 additional ADSs issued upon the exercise in full by the underwriters of their option to purchase additional ADSs. The total gross proceeds from the offering were $146.6 million. All ADSs sold in the offering were offered by COMPASS. The ADSs began trading on the Nasdaq Global Select Market on 18 September 2020.

Business highlights

We have continued to make steady progress with our phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression. We are opening a new trial site in Berlin, Germany, this month, bringing our trial to 21 sites in 10 countries. While the COVID-19 pandemic has impacted our trial, our plan to report data from this trial in late 2021 remains unchanged. We are working closely with our trial sites to carefully assess the ongoing COVID-19 situation and will always put the safety of patients and our teams above everything else.

Our team has continued to expand and we have been pleased to welcome several new colleagues to our leadership team during the quarter and post-period. Linda McGoldrick joined our board of directors in September 2020, bringing healthcare and life sciences experience from a range of public and private companies, and non-profit organisations, including Financial Health Associates International, Zillion Inc, Veos plc, and Kaiser Permanente International. In 2018, Linda was appointed by the Governor of Massachusetts to serve on the state’s Health Information Technology Commission. Greg Ryslik PhD joined us on 9 November 2020 as Senior Vice President, Data Science, Machine Learning and Digital Health Research, and Stephen Schultz will join us on 1 December 2020 as Senior Vice President, Investor Relations. Greg is a data scientist and AI (artificial intelligence) executive; he is an instructor at Stanford Continuing Studies and has held senior positions at Mindstrong and at Tesla Inc. Stephen has more than 30 years’ experience in investor relations and joins us from GW Pharmaceuticals; he has previously held senior roles at Amarin Corporation, Acusphere, and Shareholder.com. Earlier in the quarter, Steve Levine MD joined us as Vice President, Patient Access; Steve was formerly Founder and CEO at Actify Neurotherapies. Sarah Bateup was appointed Head of Therapy Research and Training, having previously been Chief Clinical Officer at Ieso Digital Health.

On 5 August 2020, we entered into a sponsored research agreement with the University of the Sciences in Philadelphia, PA, to establish a Drug Discovery Center. The Center is exploring and developing optimised psychedelic and other early stage compounds targeting the 5HT2A receptor, a receptor in the brain that is recognised as a promising target in the treatment of mental health illnesses.

In July 2020, we were granted our second UK patent, adding to our US patent and German utility model, and including claims covering crystalline psilocybin, pharmaceutical formulations, medical uses, and a method of manufacturing. Our US patent, granted in December 2019, was the subject of a petition for post grant review, filed on 21 February 2020; the petition was dismissed on the merits on 20 August 2020.

We continue to work with a number of academic and other partners to accelerate research or to provide our COMP360 psilocybin for use in their independent studies. We are providing funding and support to the Aquilino Cancer Center at Adventist HealthCare Shady Grove Medical Center, in Rockville, MD, which recently launched the first clinical trial of psilocybin therapy with simultaneous administration and one-on-one patient support to treat depression in cancer patients.

Earlier this month, we joined the Psychiatry Consortium, an international collaboration of medical research charities and pharmaceutical companies focused on the challenge of identifying and validating novel drug targets to address the unmet therapeutic needs of people living with mental health conditions. We will work alongside Psychiatry Consortium members and academic partners to advance research projects, providing support through access to funding, expertise, and commercialisation know-how. The Psychiatry Consortium seeks project proposals from the global psychiatric research community via biannual open calls for applications – the next call for applications will open in January 2021.

Financial highlights

Cash position: We held cash and cash equivalents of $196.5 million as of 30 September 2020, compared with $67.6 million at 30 June 2020. This is expected to fund operations into 2023.

Research & development expenses: R&D expenses were $6.9 million for the three months ended 30 September 2020, compared with $3.1 million during the same period in 2019. The change was primarily related to increased activities associated with our ongoing development of COMP360, increased share-based compensation, and other increases in personnel costs to support the development of COMP360.

R&D expenses were $18.8 million for the nine months ended 30 September 2020, compared with $8.0 million during the same period in 2019. The change was primarily related to increased activities associated with our ongoing development of COMP360, increased share-based compensation, and other increases in personnel costs to support the development of COMP360.

General and administrative expenses: G&A expenses were $6.6 million for the three months ended 30 September 2020, compared with $3.1 million during the same period in 2019. $2.1 million of the increase was related to share-based compensation expenses, and there were also increases in legal and professional fees, personnel and consulting expenses, and facilities costs.

G&A expenses were $21.1 million for the nine months ended 30 September 2020, compared with $5.9 million during the same period in 2019. $9.7 million of the increase was related to share-based compensation expenses, and there were also increases in legal and professional fees, personnel and consulting expenses, and facilities costs.

Other income (expense), net: Other income (expense), net was a net expense of $3.1 million for the three months ended 30 September 2020, compared with a net income of $0.6 million during the same period in 2019. $4.3 million of the increase in net expense related to foreign exchange losses.

Other income (expense), net was a net expense of $1.5 million for the nine months ended 30 September 2020, compared with a net income of $1.9 million during the same period in 2019. $3.3 million of the increase in net expense related to foreign exchange losses.

Net loss: The net loss for the three months ended 30 September 2020 was $16.7 million, or $1.30 loss per share, (after including non-cash share-based compensation expense of $5.2 million), compared with $5.7 million, or $0.73 loss per share, during the same period in 2019 (after including non-cash share-based compensation expense of $1.8 million).

The net loss for the nine months ended 30 September 2020 was $41.5 million, or $3.90 loss per share, (after including non-cash share-based compensation expense of $16.6 million), compared with $12.0 million, or $1.68 loss per share, during the same period in 2019, (after including non-cash share-based compensation expense of $2.5 million).

Conference call

The COMPASS Pathways management team will host a conference call at 1.00pm GMT (8.00am ET) on 12 November 2020. The call can be accessed by dialling (833) 665-0659 from the United States, +1 (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 9377988.

The call will also be webcast live on the investors section of the COMPASS Pathways website (ir.compasspathways.com). The webcast will be archived for 30 days.

 

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 21 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. www.compasspathways.com

 

Availability of other information about COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (Linkedin), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

 

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements.

These risks, uncertainties, and other factors include, among others: preclinical and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s Prospectus filed with the US Securities and Exchange Commission (SEC) on 21 September 2020 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof.

 

Enquiries

COMPASS Pathways
Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Amy Lawrence, amy@compasspathways.com, +44 7813 777919

Westwicke (for investor enquiries)
Stephanie Carrington, stephanie.carrington@westwicke.com, +1 646 277 1282

Posted on

TRYP APPOINTS DR. JIM GILLIGAN, PHD, MBIS, AS PRESIDENT AND CHIEF SCIENTIFIC OFFICER

La Jolla, California–(Newsfile Corp. – November 12, 2020) – Tryp Therapeutics, a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has appointed Dr. Jim Gilligan as President and Chief Scientific Officer.

Dr. Gilligan brings over 30 years of drug development activities including pharmacology, preclinical activities, CMC manufacturing, clinical phase I-III, as well as US and international regulatory strategies. A tangible result of this broad-based experience is reflected in the fact that he was a co-founder of Unigene Laboratories, the first company to have a recombinant peptide product (Fortical®) approved by the FDA via the 505(b)(2) NDA route.

Dr. James Kuo, MD, MBA, Tryp’s CEO states, “We are fortunate to have found someone of Dr. Gilligan’s vast experience in drug development and regulatory expertise. His particular knowledge in 505(b)(2) NDA drug development will be critical in the advancement of our two drug programs, which have a similar regulatory strategy. We couldn’t be more excited to welcome him to our team.”

Jim transitioned from research and development to business development and during this time obtained a Masters in International Business from Seton Hall University. As VP Product and Business Development, he established a biotech joint venture which led to him co-founding Herborium Inc., a company involved in the development of Botanical Therapeutics™.

Mr. Gilligan was responsible for executing numerous feasibility and licensing deals with the pharma industry. As part of his business development responsibilities he worked frequently with investment bankers, venture capitalists, and investment advisors. Additionally, Jim was a co-founder and CSO of Tarsa Therapeutics that completed the phase III ORACAL study as well the NDA submission for TBRIA an oral formulation of recombinant salmon calcitonin for the treatment of postmenopausal osteoporosis.

Dr. Jim Gilligan, President and CSO states, “I am excited to join this team of seasoned bio-executive professionals dedicated to bringing forward innovative drug candidates addressing diseases with significant unmet medical needs. To be at the forefront of this new and emerging psychedelic renaissance in biotech and drug development provides a unique opportunity to continue the groundbreaking research surrounding psychedelics and explore the potential of Psilocybin in the treatment of a wide range of serious diseases.”

Dr. Gilligan received his PhD in Pharmacology and Toxicology from the University of Connecticut where his research focus was cardiovascular disease, in particular atherosclerosis. He continued his post graduate education at the Roche Institute of Molecular Biology where his post-doctoral research explored changes that occur in blood vessels during the development of hypertension.

About Tryp Therapeutics:

Tryp Therapeutics is a pharmaceutical company focused on identifying and developing clinical-stage compounds. It is led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.

Contact:

TRYP Therapeutics Inc.
Investor Relations
T: 1-833-811-TRYP (8797)
E: investors@tryptherapeutics.com
W: www.tryptherapeutics.com

Cautionary Statement:

Forward-looking information

This news release contains forward-looking information relating to the Company’s proposed activities and other statements that are not historical facts. Forward-looking information relates to management’s future outlook and anticipated events or results and includes statements or information regarding the future plans or prospects of the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. These factors include risks and uncertainties associated with or arising as a result of delays in obtaining or an inability to obtain required regulatory approvals, access to sufficient quantities of cannabis, the results of diligence investigations, the actions of third parties, the results of negotiations with third parties, developments in the cannabis sector, the ability to access sufficient capital from internal and external sources, reliance on key personnel, regulatory risks and delays and other risks and uncertainties discussed in the management discussion and analysis section of the Company’s interim and most recent annual financial statement or other reports and filings, including those made with the CSE and applicable Canadian securities regulators. There can be no assurance that such forward looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information.

Posted on

NEONMIND OBTAINS HEALTH CANADA APPROVAL TO ADVANCE PSILOCYBIN RESEARCH

Vancouver, B.C. – November 12, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind”) has obtained Health Canada approval to advance its preclinical trial on psilocybin-based research (the “Trial”).

The Trial is intended to determine the capacity of psilocybin to dose-dependently cause weight loss and prevent weight gain, measuring glucose metabolism, weight loss and effect on food cravings.

NeonMind has engaged the University of British Columbia (the “University”) to conduct the Trial. The services are provided by the University under the supervision of Dr. Alasdair Barr, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, who is authorized by Health Canada to act as the Principal Investigator for the Trial (the “Principal Investigator”).

Dr. Barr is a tenured faculty member at the University and has extensive experience working with controlled substances as part of his research. His doctoral and post-doctoral research involved a significant body of work using controlled substances.

Before psilocybin, a restricted substance, can be used for a scientific purpose in Canada, the Canadian Minister of Health must grant authority or an exemption pursuant to Subsection 56 of the Controlled Drugs and Substances Act, S.C. 1996, c. 19.

On July 27, 2020, an application regarding the NeonMind Trial was submitted to Health Canada and on October 7, 2020, pursuant to section J.01.059 of Part J of the Food and Drug Regulations (FDR), Health Canada granted authorization to the Principal Investigator to carry out the Trial using psilocybin at UBC.

 

About NeonMind Biosciences Inc.

The NeonMind team marries ancient Ayurvedic wisdom with modern science, delivering high quality formulations that put health and wellness at the forefront for each of its unique coffee blends. In addition to its medicinal mushroom products, NeonMind is developing patent pending intellectual property for therapeutic uses of psilocybin, the psychedelic substance in magic mushrooms. Health Canada has approved NeonMind’s preclinical trial for research into using  psilocybin as a treatment for weight loss and NeonMind is currently developing protocols for Phase II human trials to be submitted for approval in early 2021.

NeonMind’s product candidates with psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (CDSA) and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug.

 

About Better Plant Sciences Inc.

Better Plant Sciences Inc. offers a collection of high-efficacy, plant-based products for optimum health and wellness.  We are a vertically-integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products.  We are committed to staying at the forefront of plant-science research and development, and are constantly engaged in research to further expand our portfolio of proprietary formulations and pending patents. Our all natural products vary in use from pain treatment to disease prevention to health optimization, all without chemicals or harmful ingredients.  We have an extensive catalogue of over 400 proprietary product formulas.  We currently have over 80 plant-based products for body, baby, and home for sale through e-commerce or in retail stores under the brands JUSU, Urban Juve, and Wright & Well. Better Plant owns approximately 52% of NeonMind’s issued and outstanding shares.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for Better Plant’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

HAVN LIFE ANNOUNCES LAUNCH OF A RANGE OF NATURAL HEALTH PRODUCTS

The 7 initial formulations are designed to support and enhance memory and brain function, the immune system, energy levels, and overall wellness, while reducing the negative impacts of stress.

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce its initial seven natural health supplements.

These seven products will be Havn Life’s first natural health products to launch in 2021. Each product has been thoughtfully formulated with adaptogens and antioxidants to aid in overall health and wellness and support human optimization. The initial product launch includes;

  • Mind Mushroom: A blend of four mushrooms, mind is designed to help balance the immune system, fight cell damage and increase energy.
  • Bacopa Brain: Bacopa is a powerful plant extract that is clinically proven to support cognitive function and the nervous system.
  • Rhodiola Relief: Formulated to support mental focus and mental stamina.
  • Cordyceps Perform: Cordyceps mushrooms help support a healthy immune system.
  • Chaga Immunity: Chaga mushrooms help stimulate the immune system and control inflammation in the body.
  • Reishi Recharge: this multi-purpose mushroom has also been used in Traditional Chinese Medicines to strengthen the heart to reduce fatigue, insomnia and appetite as well as coughs and wheezing.
  • Lion’s Mane Memory: Lion’s mane helps maintain and balance the immune system.

“The Havn Life Team has worked diligently to develop formulations that not only enhance and aid in human performance, but also provide overall health and wellness benefits,” said Chief Executive Officer, Tim Moore. “Havn Life’s team has done an incredible job bringing a complete and wide range of initial products to launch in 2021. The team will continue to work on additional formulations and products that will be launched later in 2021.“

Furthermore, the Company has now received approval from Health Canada for all seven products for launch in 2021 and will provide further updates on its initial launch in the Canadian market.

On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

Connect

Investor Relations
ir@havnlife.com
604 (687)-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

Posted on

Vireo Health to Report Third Quarter 2020 Results on November 25, 2020

MINNEAPOLIS, Nov. 11, 2020 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO, OTCQX: VREOF), the science-focused multi-state cannabis company with active operations in exclusively medical-only markets and licenses in seven states and the commonwealth of Puerto Rico, today announced that it will report financial results for its third quarter ended September 30, 2020 on Wednesday, November 25, 2020 before the market opens.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

The Company will hold a conference call and webcast to discuss its business and financial results that same day at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). Interested parties may register to attend the conference call via the following link: http://www.directeventreg.com/registration/event/8084816. Upon registration, each participant will be provided with call details and a registrant ID for Vireo’s conference ID number 8084816. A live audio webcast of the call will also be available in the Events & Presentations section of Vireo’s website at https://investors.vireohealth.com/events-and-presentations/default.aspx. A webcast replay will be made available for one year on Vireo’s website.

About Vireo Health International, Inc.

Vireo Health International, Inc. (“Vireo” or the “Company”) is a physician-led cannabis company focused on bringing the best of technology, science, and engineering to the cannabis industry. Vireo manufactures proprietary, branded cannabis products in environmentally-friendly, state-of-the-art greenhouses and distributes its products through its growing network of Green Goods™ retail dispensaries and through hundreds of third-party dispensaries in seven states. Vireo’s team of more than 300 employees, led by scientists, engineers, and cultivation experts, is focused on efficiency and the creation of best-in-class products, while driving scientific innovation within the cannabis industry and developing meaningful intellectual property. Today, Vireo is licensed to grow and/or process cannabis in eight markets. The Company is operational in seven of those eight markets – including the core markets of Arizona, Maryland, Minnesota, New Mexico, New York, Pennsylvania. The Company holds 32 total retail dispensary licenses, of which 13 are currently open for business. For more information about Vireo Health, please visit www.vireohealth.com.

Contact Information

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-to-report-third-quarter-2020-results-on-november-25-2020-301170903.html

SOURCE Vireo Health International, Inc.